Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202609049 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 New Drug Phase Ⅲ
N202609085 An open-label, single-dose study to characterize the pharmacokinetics and safety of NH002 in healthy volunteers and participants with compromised pulmonary conditions New Drug Phase Ⅰ
N202609086 A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02 New Drug Phase Ⅲ
N202610001 A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of secutrelvir in participants with COVID-19 New Drug Phase Ⅲ
N202610012 A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) New Drug Phase Ⅲ
N202610014 An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT] New Drug Phase Ⅲ
N202610024 A randomized, open-label (unblinding), four-period, fully replicated, crossover bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202610025 A preliminary bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202610037 An Open-Label, Randomized, and Crossover Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Film-Coated Tablets in Healthy Subjects under Fasting Conditions Bioavailability / Bioequivalence (BA/BE) NA
N202610045 A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013) New Drug Phase Ⅲ
1 2 25 26 27 28 29 30 31 32 33 34 / 34

TOP